Q4 2025 13F Holders as of 31 Dec 2025
-
Type / Class
-
Equity / Common Stock, $0.01 par value per share
-
Shares outstanding
-
209,618,986
-
Total 13F shares
-
1,953,989
-
Share change
-
-1,939,641
-
Total reported value
-
$15,237,446
-
Price per share
-
$7.80
-
Number of holders
-
12
-
Value change
-
-$15,117,496
-
Number of buys
-
4
-
Number of sells
-
10
Institutional Holders of BIOCRYST PHARMACEUTICALS INC - Common Stock, $0.01 par value per share (BCRX) as of Q4 2025
As of 31 Dec 2025,
BIOCRYST PHARMACEUTICALS INC - Common Stock, $0.01 par value per share (BCRX) was held by
12 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
1,953,989 shares.
The largest 10 holders included
Aberdeen Group plc, Assenagon Asset Management S.A., DOLIVER ADVISORS, LP, SG Americas Securities, LLC, Hennion & Walsh Asset Management, Inc., Counterweight Ventures, LLC, Empirical Financial Services, LLC d.b.a. Empirical Wealth Management, Cypress Wealth Services, LLC, WEALTH ENHANCEMENT ADVISORY SERVICES, LLC, and NISA INVESTMENT ADVISORS, LLC.
This page lists
12
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.